Virus-specific T-cell therapy (St. Anna Kinderkrebsforschung)

N/A

Report date: 2022/01/14 13:23:58

Base Information

Drug NameVirus-specific T-cell therapy (St. Anna Kinderkrebsforschung)

Drug Alias NameN/A

ClassificationCell and gene therapy > Cell therapy > Donor > AllogeneicCell and gene therapy > Cell therapy > Source of cells > PMBC-derivedCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Virus-specific T Cell therapy

Mechanisms of ActionImmunostimulantsCell replacements

TargetsNot applicable

Therapy Area/IndicationsCytomegalovirus InfectionsAdenoviridae Infections

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryAustria

CombinationsNo

Global Highest StatusDiscontinued (Phase 2 Clinical)

Highest Status in ChinaN/A

Originator CompaniesSt. Anna Kinderkrebsforschung

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesSt. Anna Kinderkrebsforschung

Active IndicationsN/A

Inactive IndicationsCytomegalovirus InfectionsAdenoviridae Infections

Other Information

ATC CodeN/A